REFLECT II: A randomized trial of a cerebral embolic protection device during TAVR

Reported from the TCT Congress 2020

At TCT Connect 2020, Jeffrey Moses presented the results of the REFLECT II trial. Mirvat Alasnag provides a summary of the key messages.

REFLECT II is a randomized clinical trial evaluating the safety and efficacy of a device designed to reduce cerebral embolization and ischemic stroke, complications of transcatheter aortic valve replacement (TAVR).

Results showed that the device met the primary safety endpoint compared to historical controls but did not demonstrate superiority of the device for the primary hierarchical efficacy endpoint.

In this video, Mirvat Alasnag summarizes the key messages.